北卡罗来纳州

我们是谁

  • 4 月 5, 2022
    对晚期实体瘤患者进行的 GSK4381562 首次人体研究
  • 4 月 5, 2022
    Repotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
  • 4 月 5, 2022
    TAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况
  • 4 月 5, 2022
    A Study of NX-1607 in Adults With Advanced Malignancies
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 4 月 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
  • 4 月 5, 2022
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
  • 1 月 1, 1970
    A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors